Madrigal Pharmaceuticals, Inc. (MDGL)

NASDAQ: MDGL · IEX Real-Time Price · USD
76.71
+3.37 (4.60%)
At close: Aug 15, 2022 4:00 PM
77.69
+0.98 (1.28%)
After-hours: Aug 15, 2022 5:32 PM EDT
4.60%
Market Cap 1.31B
Revenue (ttm) n/a
Net Income (ttm) -255.90M
Shares Out 17.10M
EPS (ttm) -14.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 181,294
Open 72.47
Previous Close 73.34
Day's Range 72.47 - 78.12
52-Week Range 52.33 - 105.93
Beta 1.04
Analysts Buy
Price Target 159.04 (+107.3%)
Earnings Date Aug 3, 2022

About MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with... [Read more...]

Industry Biotechnology
Founded 2011
CEO Rebecca Taub
Employees 71
Stock Exchange NASDAQ
Ticker Symbol MDGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is 159.04, which is an increase of 107.33% from the latest price.

Price Target
$159.04
(107.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis...

Trial Results Set to Make or Break Small-Cap Pharma Stocks

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration...

Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details o...

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International...

CONSHOHOCKEN, Pa., June 25, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis...

Madrigal Pharmaceuticals Supports International NASH Day on June 9

Company expands its partnerships with leading patient advocacy groups to improve NASH education and patient care Company expands its partnerships with leading patient advocacy groups to improve NASH edu...

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatit...

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatiti...

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

Company to host conference call at 8:00 AM ET, May 9th, 2022

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepati...

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financi...

CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatiti...

3 Graham's Lost Formula Stocks to Consider for February

After seeing a sell-off for most of January, two market indexes rose for the fourth day in a row on Wednesday. The S&P 500 Index was up 13.95 points, or 0.31%, while the tech-heavy Nasdaq Composite gain...

Other symbols: DNOWSKIL

Why Madrigal Pharmaceuticals Stock Briefly Spiked Today

A positive data readout from a phase 3 clinical trial propelled the drugmaker's shares higher.

Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health

Madrigal Pharmaceuticals Inc MDGL has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom.  [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistica...

Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom:

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, ...

CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans...

3 Biotech Stocks With Major Catalysts in January

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

Other symbols: ICPTNVAX

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022 Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty ...

Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results

Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AASLD's upcoming The Liver Meeting® 2021 Several abstracts with data from the open-l...

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation's Screening Fund to Improve Diagnosis and Stagin...

In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH In recognition of Liver Awareness Month, Madrigal and Fatty Live...

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update

CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishme...

Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer

CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with h...

Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...

Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3...

CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study...

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-N...

CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH...